Literature DB >> 25321327

Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.

Joo Y Song1, Stefania Pittaluga, Kieron Dunleavy, Nicole Grant, Therese White, Liuyan Jiang, Theresa Davies-Hill, Mark Raffeld, Wyndham H Wilson, Elaine S Jaffe.   

Abstract

Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder. It is hypothesized that these patients have dysregulated immune surveillance of EBV. We reviewed the biopsies of 55 patients with LYG who were referred for a prospective trial at the National Cancer Institute (1995 to 2010) and evaluated the histologic, immunohistochemical, in situ hybridization, and molecular findings of these biopsies in conjunction with clinical information. Grading of the lesions was based on morphologic features and the number of EBV-positive B cells. The median age was 46 years (M:F 2.2:1). Clinically, all patients had lung involvement (100%), with the next most common site being the central nervous system (38%). No patient had nodal or bone marrow disease. All patients had past EBV exposure by serology but with a low median EBV viral load. We reviewed 122 biopsies; the most common site was lung (73%), followed by skin/subcutaneous tissue (17%); other sites included kidney, nasal cavity, gastrointestinal tract, conjunctiva, liver, and adrenal gland. Histologically, the lesions showed angiocentricity, were rich in T cells, had large atypical B cells, and were positive for EBV. Grading was performed predominantly on the lung biopsy at diagnosis; they were distributed as follows: LYG grade 1 (30%), grade 2 (22%), and grade 3 (48%). Necrosis was seen in all grades, with a greater degree in high-grade lesions. Immunoglobulin gene rearrangement studies were performed, and a higher percentage of clonal rearrangements were seen in LYG grade 2 (50%) and grade 3 (69%) as compared with grade 1 (8%). LYG is a distinct entity that can usually be differentiated from other EBV-associated B-cell lymphoproliferative disorders on the basis of the combination of clinical presentation, histology, and EBV studies. Grading of these lesions is important because it dictates the treatment choice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25321327      PMCID: PMC4293220          DOI: 10.1097/PAS.0000000000000328

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  36 in total

1.  Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations.

Authors:  P Lardelli; M A Bookman; J Sundeen; D L Longo; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1990-08       Impact factor: 6.394

2.  Lymphomatoid granulomatosis.

Authors:  A A Liebow; C R Carrington; P J Friedman
Journal:  Hum Pathol       Date:  1972-12       Impact factor: 3.466

3.  Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis.

Authors:  D Guinee; E Jaffe; D Kingma; N Fishback; K Wallberg; J Krishnan; G Frizzera; W Travis; M Koss
Journal:  Am J Surg Pathol       Date:  1994-08       Impact factor: 6.394

4.  Lymphomatoid granulomatosis: a T-cell disorder?

Authors:  P W Nichols; M Koss; A M Levine; R J Lukes
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

5.  Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.

Authors:  E H Lipford; J B Margolick; D L Longo; A S Fauci; E S Jaffe
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

6.  Angiocentric immunoproliferative lesion (lymphomatoid granulomatosis). A cytogenetic, immunophenotypic, and genotypic study.

Authors:  L R Donner; S Dobin; D Harrington; S Bassion; E S Rappaport; R F Peterson
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

7.  Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics.

Authors:  P P Sordillo; B Epremian; B Koziner; M Lacher; P Lieberman
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

8.  Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases.

Authors:  A L Katzenstein; C B Carrington; A A Liebow
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

9.  Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms.

Authors:  I Ramasamy; M Brisco; A Morley
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

10.  Polymorphic reticulosis, lymphomatoid granulomatosis. Two diseases or one?

Authors:  R A DeRemee; L H Weiland; T J McDonald
Journal:  Mayo Clin Proc       Date:  1978-10       Impact factor: 7.616

View more
  20 in total

1.  Primary central nervous system lymphomatoid granulomatosis: a case report.

Authors:  Yuanyuan Xiang; Peng Yan; Shan Li; Yuan Xue; Cuicui Liu; Jifeng Li; Qinjian Sun; Yifeng Du; Xiaohui Liu
Journal:  Neurol Sci       Date:  2020-10-20       Impact factor: 3.307

Review 2.  Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder.

Authors:  Christopher Melani; Elaine S Jaffe; Wyndham H Wilson
Journal:  Blood       Date:  2020-04-16       Impact factor: 22.113

Review 3.  Noninfectious Granulomatous Diseases of the Chest.

Authors:  Muhammad Naeem; David H Ballard; Hamza Jawad; Constantine Raptis; Sanjeev Bhalla
Journal:  Radiographics       Date:  2020-06-05       Impact factor: 5.333

Review 4.  New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders.

Authors:  Leticia Quintanilla-Martinez; Steven H Swerdlow; Thomas Tousseyn; Carlos Barrionuevo; Shigeo Nakamura; Elaine S Jaffe
Journal:  Virchows Arch       Date:  2022-10-11       Impact factor: 4.535

5.  Porta Hepatis Mass.

Authors:  Steve M Niemiec; Joseph M Vinetz; Jason K Sicklick
Journal:  JAMA Surg       Date:  2016-02       Impact factor: 14.766

6.  Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman.

Authors:  Michael D Abendroth; Michael G Bayerl; Michael J Wilkinson; David F Claxton; Charles S Specht
Journal:  Ocul Oncol Pathol       Date:  2017-08-11

7.  Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement.

Authors:  Jesse Mooneyham; Cesar Gentille; Andrea Barbieri; Shilpan Shah
Journal:  BMJ Case Rep       Date:  2020-09-07

8.  Angioinvasive lymphoma (lymphomatoid granulomatosis) in a cat, with cutaneous and ocular metastasis.

Authors:  Rebecca Bacon; Vinay Shivanna; Misty Gore; Jamie Henningson; Charan Ganta
Journal:  J Vet Diagn Invest       Date:  2021-02-10       Impact factor: 1.279

Review 9.  Systematic Review of Spinal Lymphomatoid Granulomatosis Cases.

Authors:  Naotaka Iwamoto; Kyongsong Kim; Rinko Kokubo; Toyohiko Isu; Daijiro Morimoto; Tomoko Omura; Koji Saito; Yoshinao Kikuchi; Yasunori Ota; Akira Matsuno; Akio Morita
Journal:  World Neurosurg X       Date:  2021-04-30

10.  Pulmonary lymphomatoid granulomatosis: An uncommon disease but not to be forgotten-a single centre experience.

Authors:  Pradeep Balakrishnan; Matthew Ing; Zaid Househ; Ajantha Raguparan
Journal:  Respirol Case Rep       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.